A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

Takashi Yokoi, Takeshi Tamaki, Toshiki Shimizu, Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Moriguchi City, Osaka, JapanBackground: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yokoi T, Tamaki T, Shimizu T, Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/66978b224fa6412a821f19f149590fb4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66978b224fa6412a821f19f149590fb4
record_format	dspace
spelling	oai:doaj.org-article:66978b224fa6412a821f19f149590fb42021-12-02T06:27:11ZA pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer1179-2728https://doaj.org/article/66978b224fa6412a821f19f149590fb42012-05-01T00:00:00Zhttp://www.dovepress.com/a-pilot-study-of-a-metronomic-chemotherapy-regimen-with-weekly-low-dos-a9925https://doaj.org/toc/1179-2728Takashi Yokoi, Takeshi Tamaki, Toshiki Shimizu, Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Moriguchi City, Osaka, JapanBackground: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic agent without a long interval.Purpose: The aim of this clinical pilot study was to evaluate the toxicity and efficacy of LDM chemotherapy with weekly low-dose docetaxel for previously treated non-small cell lung cancer (NSCLC).Patients and methods: The enrolled patients received 15 mg/m2 of docetaxel intravenously on a weekly basis without any interval.Results: Twenty-seven patients were enrolled in the study; 20 were men, and seven were women. The median age was 62 years (range: 32&ndash;75). Eleven patients were stage IIIB, and 16 were stage IV. The Eastern Cooperative Oncology Group performance status was 0 or 1. There was no severe hematological adverse effect; importantly, there was no neutropenia or thrombocytopenia. The objective response rate was 7.4% and the disease control rate was 51.9%. The median survival time was 16.4 months (95% CI: 5.7&ndash;36.4).Conclusion: Our preliminary results indicate that our metronomic regimen was well tolerated and active in patients with previously treated NSCLC. Thus, further investigation of this LDM regimen is warranted.Keywords: optimal biological dose, metronomic chemotherapy, docetaxelYokoi TTamaki TShimizu TNomura SDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 15-20 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yokoi T Tamaki T Shimizu T Nomura S A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
description	Takashi Yokoi, Takeshi Tamaki, Toshiki Shimizu, Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Moriguchi City, Osaka, JapanBackground: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic agent without a long interval.Purpose: The aim of this clinical pilot study was to evaluate the toxicity and efficacy of LDM chemotherapy with weekly low-dose docetaxel for previously treated non-small cell lung cancer (NSCLC).Patients and methods: The enrolled patients received 15 mg/m2 of docetaxel intravenously on a weekly basis without any interval.Results: Twenty-seven patients were enrolled in the study; 20 were men, and seven were women. The median age was 62 years (range: 32&ndash;75). Eleven patients were stage IIIB, and 16 were stage IV. The Eastern Cooperative Oncology Group performance status was 0 or 1. There was no severe hematological adverse effect; importantly, there was no neutropenia or thrombocytopenia. The objective response rate was 7.4% and the disease control rate was 51.9%. The median survival time was 16.4 months (95% CI: 5.7&ndash;36.4).Conclusion: Our preliminary results indicate that our metronomic regimen was well tolerated and active in patients with previously treated NSCLC. Thus, further investigation of this LDM regimen is warranted.Keywords: optimal biological dose, metronomic chemotherapy, docetaxel
format	article
author	Yokoi T Tamaki T Shimizu T Nomura S
author_facet	Yokoi T Tamaki T Shimizu T Nomura S
author_sort	Yokoi T
title	A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
title_short	A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
title_full	A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
title_fullStr	A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
title_full_unstemmed	A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
title_sort	pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/66978b224fa6412a821f19f149590fb4
work_keys_str_mv	AT yokoit apilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT tamakit apilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT shimizut apilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT nomuras apilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT yokoit pilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT tamakit pilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT shimizut pilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer AT nomuras pilotstudyofametronomicchemotherapyregimenwithweeklylowdosedocetaxelforpreviouslytreatednonsmallcelllungcancer
_version_	1718399936645562368

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

Ejemplares similares